PL2532367T3 - Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu - Google Patents
Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworuInfo
- Publication number
- PL2532367T3 PL2532367T3 PL11739883T PL11739883T PL2532367T3 PL 2532367 T3 PL2532367 T3 PL 2532367T3 PL 11739883 T PL11739883 T PL 11739883T PL 11739883 T PL11739883 T PL 11739883T PL 2532367 T3 PL2532367 T3 PL 2532367T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical agent
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010023455 | 2010-02-04 | ||
EP11739883.4A EP2532367B1 (en) | 2010-02-04 | 2011-02-04 | Pharmaceutical agent for treatment and/or prevention of cancer |
PCT/JP2011/052414 WO2011096535A1 (ja) | 2010-02-04 | 2011-02-04 | 癌の治療及び/又は予防のための医薬品 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2532367T3 true PL2532367T3 (pl) | 2019-02-28 |
Family
ID=44355529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11739883T PL2532367T3 (pl) | 2010-02-04 | 2011-02-04 | Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu |
Country Status (16)
Country | Link |
---|---|
US (1) | US9180187B2 (pl) |
EP (1) | EP2532367B1 (pl) |
JP (1) | JP5923984B2 (pl) |
KR (1) | KR101843807B1 (pl) |
CN (2) | CN102844048A (pl) |
AU (1) | AU2011211700B2 (pl) |
BR (1) | BR112012018943A8 (pl) |
CA (1) | CA2788720C (pl) |
DK (1) | DK2532367T3 (pl) |
ES (1) | ES2691738T3 (pl) |
HU (1) | HUE040012T2 (pl) |
MX (1) | MX2012008991A (pl) |
PL (1) | PL2532367T3 (pl) |
PT (1) | PT2532367T (pl) |
RU (1) | RU2624029C2 (pl) |
WO (1) | WO2011096535A1 (pl) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2570731T3 (es) | 2008-08-05 | 2016-05-20 | Toray Industries | Método de detección de cáncer |
KR101667319B1 (ko) | 2008-08-05 | 2016-10-18 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
AU2011211699B2 (en) | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
PT2532366T (pt) | 2010-02-04 | 2016-12-20 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção de cancro |
US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
PL2532365T3 (pl) | 2010-02-04 | 2016-12-30 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
CA2788720C (en) | 2010-02-04 | 2019-08-20 | Takayoshi Ido | Medicament for treating and/or preventing cancer |
ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
MX349907B (es) | 2011-08-04 | 2017-08-18 | Toray Industries | Metodo para detectar cancer pancreatico. |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
MX348581B (es) * | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
EP2740796B1 (en) | 2011-08-04 | 2017-05-17 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
EP2740793B1 (en) | 2011-08-04 | 2017-11-29 | Toray Industries, Inc. | Drug composition for cancer treatment and/or prevention |
DK2740795T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of cancer |
PL2818483T3 (pl) * | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
KR102009238B1 (ko) * | 2012-02-21 | 2019-08-09 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
DK2818481T3 (da) * | 2012-02-21 | 2019-10-14 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
RU2633505C2 (ru) * | 2012-02-21 | 2017-10-12 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
KR102155531B1 (ko) * | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
MX357965B (es) * | 2012-03-30 | 2018-08-01 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. |
WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
CN104471404B (zh) | 2012-07-19 | 2017-03-01 | 东丽株式会社 | 癌的检测方法 |
WO2015020212A1 (ja) | 2013-08-09 | 2015-02-12 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
CN109890417A (zh) | 2016-10-28 | 2019-06-14 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
CA3095719A1 (en) * | 2018-03-30 | 2019-10-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
BR112022018171A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
EP4119158A1 (en) | 2020-03-12 | 2023-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
US20230139178A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
US20230129035A1 (en) | 2020-03-12 | 2023-04-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2022270524A1 (pl) | 2021-06-23 | 2022-12-29 | ||
CN117545508A (zh) | 2021-06-23 | 2024-02-09 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
AU2022319362A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
WO2023008461A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
WO2024048541A1 (ja) * | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2024048542A1 (ja) * | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE449342T1 (de) * | 1994-09-19 | 2009-12-15 | Ricardo J Moro | Nachweis von krebs |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
HUP0203035A3 (en) | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
WO2000060077A2 (en) | 1999-04-02 | 2000-10-12 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
JP2003528587A (ja) | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 27個のヒト分泌タンパク質 |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001072295A2 (en) | 2000-03-29 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
EP2179742A1 (en) | 2002-11-26 | 2010-04-28 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
JP2008506352A (ja) | 2004-01-26 | 2008-03-06 | デビオビジョン・インコーポレーテッド | 新生物特異的ポリペプチド及びその使用 |
DK1735348T3 (da) | 2004-03-19 | 2012-07-16 | Imclone Llc | Humant anti-epidermalt vækstfaktorreceptorantistof |
WO2005100998A2 (en) * | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
CN101141981A (zh) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CA2598217A1 (en) | 2005-02-18 | 2006-08-24 | Marsha A. Moses | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
EP1991701A4 (en) * | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER |
US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
KR101667319B1 (ko) * | 2008-08-05 | 2016-10-18 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
ES2570731T3 (es) | 2008-08-05 | 2016-05-20 | Toray Industries | Método de detección de cáncer |
PL2837383T3 (pl) | 2008-08-05 | 2017-07-31 | Toray Industries, Inc. | Środek indukujący odporność |
JP5734978B2 (ja) | 2009-08-19 | 2015-06-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Ffpe材料におけるインテグリン複合体検出のための抗体 |
PL2480671T3 (pl) | 2009-09-22 | 2015-12-31 | Probiogen Ag | Proces produkcji cząsteczek zawierających specjalne struktury glikanowe |
AU2011211682B2 (en) * | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
AU2011211699B2 (en) | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
CA2788720C (en) | 2010-02-04 | 2019-08-20 | Takayoshi Ido | Medicament for treating and/or preventing cancer |
PL2532365T3 (pl) | 2010-02-04 | 2016-12-30 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
US8709418B2 (en) * | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
PT2532366T (pt) | 2010-02-04 | 2016-12-20 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção de cancro |
MX349907B (es) | 2011-08-04 | 2017-08-18 | Toray Industries | Metodo para detectar cancer pancreatico. |
EP2740796B1 (en) | 2011-08-04 | 2017-05-17 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
KR102155531B1 (ko) | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
MX357965B (es) | 2012-03-30 | 2018-08-01 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. |
-
2011
- 2011-02-04 CA CA2788720A patent/CA2788720C/en active Active
- 2011-02-04 DK DK11739883.4T patent/DK2532367T3/en active
- 2011-02-04 ES ES11739883.4T patent/ES2691738T3/es active Active
- 2011-02-04 MX MX2012008991A patent/MX2012008991A/es active IP Right Grant
- 2011-02-04 PT PT11739883T patent/PT2532367T/pt unknown
- 2011-02-04 CN CN2011800172337A patent/CN102844048A/zh active Pending
- 2011-02-04 RU RU2012137503A patent/RU2624029C2/ru active
- 2011-02-04 PL PL11739883T patent/PL2532367T3/pl unknown
- 2011-02-04 JP JP2011510197A patent/JP5923984B2/ja active Active
- 2011-02-04 EP EP11739883.4A patent/EP2532367B1/en active Active
- 2011-02-04 AU AU2011211700A patent/AU2011211700B2/en active Active
- 2011-02-04 WO PCT/JP2011/052414 patent/WO2011096535A1/ja active Application Filing
- 2011-02-04 CN CN201910271408.5A patent/CN109925511B/zh active Active
- 2011-02-04 BR BR112012018943A patent/BR112012018943A8/pt not_active Application Discontinuation
- 2011-02-04 KR KR1020127022763A patent/KR101843807B1/ko active IP Right Grant
- 2011-02-04 US US13/576,950 patent/US9180187B2/en active Active
- 2011-02-04 HU HUE11739883A patent/HUE040012T2/hu unknown
Also Published As
Publication number | Publication date |
---|---|
CN109925511A (zh) | 2019-06-25 |
EP2532367A1 (en) | 2012-12-12 |
HUE040012T2 (hu) | 2019-02-28 |
DK2532367T3 (en) | 2018-11-19 |
RU2012137503A (ru) | 2014-03-10 |
US9180187B2 (en) | 2015-11-10 |
CA2788720C (en) | 2019-08-20 |
RU2624029C2 (ru) | 2017-06-30 |
AU2011211700B2 (en) | 2015-06-11 |
WO2011096535A1 (ja) | 2011-08-11 |
CN102844048A (zh) | 2012-12-26 |
JPWO2011096535A1 (ja) | 2013-06-13 |
JP5923984B2 (ja) | 2016-05-25 |
EP2532367A4 (en) | 2014-05-28 |
KR101843807B1 (ko) | 2018-03-30 |
KR20120139720A (ko) | 2012-12-27 |
CA2788720A1 (en) | 2011-08-11 |
BR112012018943A8 (pt) | 2017-12-19 |
PT2532367T (pt) | 2018-11-09 |
MX2012008991A (es) | 2012-09-07 |
AU2011211700A1 (en) | 2012-08-23 |
ES2691738T3 (es) | 2018-11-28 |
CN109925511B (zh) | 2024-03-19 |
US20120294860A1 (en) | 2012-11-22 |
EP2532367B1 (en) | 2018-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2532367T (pt) | Agente farmacêutico para o tratamento e/ou prevenção do cancro | |
PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
EP2818482A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
EP2818481A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
EP2824114A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
EP2740793A4 (en) | MEDICINAL PREPARATION FOR CANCER TREATMENT AND / OR PREVENTION | |
EP2740489A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA | |
PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
PL2832365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby | |
HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
IL225471B (en) | Preparations for the prevention and treatment of cancer | |
EP2532364A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
EP2322221A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER | |
GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
EP2558085A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER | |
HK1201730A1 (en) | Treatment agent and or prophylactic agent for side effects of cancer drugs | |
PL2305300T3 (pl) | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
EP2604263A4 (en) | MEDICAMENT FOR PREVENTING AND / OR TREATING HEPATOCELLULAR CARCINOMA | |
IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer | |
HU1000559D0 (en) | Pharmaceutical compositions for the treatment of osteoporosis and cancer |